European Journal of Heart Failure
The C-MIC II Follow-Up Study: Safety and Efficacy Results 12 months After Deactivation of Cardiac Microcurrent Therapy
Abstract Background The C-MIC II trial demonstrated benefits of 6 months of cardiac microcurrent (C-MIC) therapy in patients with non-ischemic heart failure with reduced ejection fraction (HFrEF). The prospective C-MIC II Follow-Up Study evaluates safety and efficacy outcomes post-device deactivation. Methods Primary safety-related endpoints included all-cause, cardiovascular and device-related mortality and hospitalizations and adverse events (AEs). Secondary efficacy-related endpoints included changes in left ven …